Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 6/20 | 0.51 |
| ▸ | ELOC | Q15369 | 3/20 | 0.40 |
| ▸ | ELOB | Q15370 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.37 |
| ▸ | CDK2 | P24941 | 8/20 | 0.37 |
| ▸ | GSK3B | P49841 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975657 | 0.90 | VHL (0.48) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL16276344 | 0.90 | VHL (0.48) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL20975656 | 0.89 | VHL (0.65) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL16276341 | 0.82 | VHL (0.42) | VHLELOCELOBPOLBKMT2A | |
| SCHEMBL21696617 | 0.79 | VHL (0.38) | VHLELOCELOB | |
| SCHEMBL21696518 | 0.74 | VHL (0.60) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL15126509 | 0.72 | VHL (0.59) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL15110656 | 0.72 | VHL (0.55) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL20975701 | 0.72 | VHL (0.55) | VHLELOCELOBCCNE1CDK2 | |
| SCHEMBL15110420 | 0.72 | VHL (0.55) | VHLELOCELOBCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | VHL 1/4885ELOC 190/4885ELOB 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.